Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. carries a market capitalization of 10.45B, placing it among publicly traded companies globally. Its enterprise value stands at 6.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.45B |
| Enterprise Value | 6.40B |
Share Statistics
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. currently has 420.01M shares outstanding.
| Shares Outstanding | 420.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. trades at a trailing price-to-earnings ratio of 22.71. The price-to-sales ratio is 5.29, and the price-to-book ratio stands at 4.99.
| PE Ratio | 22.71 |
| PS Ratio | 5.29 |
| PB Ratio | 4.99 |
| P/TBV Ratio | 3.76 |
| P/FCF Ratio | 17.15 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. trades at an EV/EBITDA multiple of 18.42 and an EV/FCF ratio of 16.23. The EV/Sales ratio of 5.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.42 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.05 |
| EV / EBITDA | 18.42 |
| EV / EBIT | 18.42 |
| EV / FCF | 16.23 |
Financial Position
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. maintains a current ratio of 2.78, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.01, indicating elevated leverage, while an interest coverage ratio of 105.16 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.78 |
| Quick Ratio | 1.54 |
| Debt / Equity | 17.01 |
| Debt / EBITDA | 0.88 |
| Interest Coverage | 105.16 |
Financial Efficiency
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. posts a return on equity of 24.79 and a return on invested capital of 15.66.
| Return on Equity (ROE) | 24.79 |
| Return on Assets (ROA) | 14.00 |
| Return on Invested Capital (ROIC) | 15.66 |
| Return on Capital Employed (ROCE) | 21.59 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.40 |
Taxes
Over the trailing twelve months, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. has paid 53.28M in income taxes, reflecting an effective tax rate of 15.26.
| Income Tax | 53.28M |
| Effective Tax Rate | 15.26 |
Stock Price Statistics
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s stock has gained approximately 16.0373% over the past 52 weeks. The 50-day moving average sits at 25.84, while the 200-day moving average is 23.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | 16.0373% |
| 50-Day Moving Average | 25.84 |
| 200-Day Moving Average | 23.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. generated 1.27B in revenue and converted that into 295.82M in net income, yielding earnings per share of 0.91. EBITDA reached 347.72M, while operating income came in at 347.72M.
| Revenue | 1.27B |
| Gross Profit | 472.88M |
| Operating Income | 347.72M |
| Pretax Income | 349.10M |
| Net Income | 295.82M |
| EBITDA | 347.72M |
| EBIT | 347.72M |
| Earnings Per Share (EPS) | 0.91 |
Balance Sheet
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. holds 620.72M in cash and equivalents against 306.85M in total debt, resulting in a net debt position of -152.33M. Total book value stands at 1.35B, with working capital of 716.14M providing operational flexibility.
| Cash & Cash Equivalents | 620.72M |
| Total Debt | 306.85M |
| Net Debt | -152.33M |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 4.13 |
| Working Capital | 716.14M |
Cash Flow
After subtracting -391.75M in capital expenditures, free cash flow totaled -391.75M - equivalent to -1.20 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -391.75M |
| Free Cash Flow | -391.75M |
| FCF Per Share | -1.20 |
Margins
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. operates with a gross margin of 37.25, reflecting its pricing power and cost economics. The operating margin of 27.39 and net profit margin of 23.30 provide insight into operational efficiency.
| Gross Margin | 37.25 |
| Operating Margin | 27.39 |
| Pretax Margin | 27.50 |
| Profit Margin | 23.30 |
| EBITDA Margin | 27.39 |
Dividends & Yields
The company's payout ratio of 22.73 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.21 |
| Dividend Yield | N/A |
| Payout Ratio | 22.73 |
| Shareholder Yield | -2.43 |
| FCF Yield | 5.83 |
Stock Splits
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s most recent stock split took place on June 6, 2024 with a 10:13 split ratio.
| Last Split Date | 6/6/2024 |
| Split Ratio | 10:13 |
Scores
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. posts an Altman Z-Score of 9.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.77 |